Table 1 Basic information of COPD patients in stable stage
From: Aspergillus fumigatus during COPD exacerbation: a pair-matched retrospective study
Aspergillus colonization, n = 23 | Control, n = 69 | p value | |
|---|---|---|---|
Demographics | |||
Age, yr (IQR) | 76 ± 7 | 75 ± 8 | 0.741 |
Gender (male/female) | 20/3 | 60/9 | 1.000 |
BMI(kg/m2) | 22.4 ± 4.1 | 23.4 ± 3.7 | 0.266 |
Smoking history, n (%) | 17 (73.9%) | 63 (91.3%) | 0.091 |
Pack-years (IQR) | 58 ± 39 | 47 ± 36 | 0.291 |
COPD characteristics (post bronchodilators) | |||
FEV1% (IQR) | 40.0 ± 16.0 | 44.5 ± 16.8 | 0.261 |
GOLD grade | |||
Grade I | 4 (17.4%) | 15 (21.7%) | |
Grade II | 5 (21.7%) | 21 (30.4%) | |
Grade III | 12 (54.5%) | 30 (51.7%) | |
Grade IV | 2 (9.1%) | 3 (5.2%) | |
GOLD grade ≥ 3, n (%) | 14 (63.6) | 33 (56.9) | 0.744 |
Underlying conditions, n (%) | |||
Hypertension | 15 (65.2%) | 41 (59.4%) | 0.806 |
Diabetes mellitus | 7 (31.8%) | 7 (15.9%) | 0.201 |
Coronary heart disease | 7 (30.4%) | 16 (23.2%) | 0.580 |
Cerebral vascular disease | 4 (17.4%) | 10 (14.5%) | 0.774 |
Chronic heart failure | 8 (34.8%) | 12 (17.4%) | 0.089 |
Peptic ulcer | 0 | 6 (8.7%) | 0.331 |
Chronic renal failure | 2 (8.7%) | 3 (4.4%) | 0.597 |
Stable period treatment | |||
Corticosteroids use, n (%) | 17 (73.9%) | 28 (40.6%) | 0.008 |
daily dose of inhaled corticosteroid >1000μg (Betamethasone equal dosage) | 56.5% | 33.3% | 0.048 |
Long term oxygen therapy | 3 (13.0%) | 12 (17.4%) | 0.753 |
Times of AECOPD in previous year | 1.7 ± 1.3 | 1.3 ± 1.1 | 0.186 |